In particular, Dr. Azad's laboratory and clinical trials
explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs.
«If the pilot trial is successful, we plan to pursue a larger trial to
explore this strategy's potential as a straightforward and cost - effective way to improve the existing
therapy for AML and MDS,» said Peter Jones, Ph.D., D.Sc., co-senior author of the PNAS study, chief scientific officer at Van Andel Research Institute (VARI) and co-leader of the Van Andel Research Institute — Stand Up To Cancer (VARI — SU2C)
Epigenetics Dream Team.